Results 161 to 170 of about 12,580 (199)

Factors associated with antibiotic prescription among patients with respiratory illness in Thailand: The potential impact of rapid influenza diagnostic testing in antimicrobial stewardship. [PDF]

Int J Infect Dis
Duanyai C, Kittikraisak W, Moolasart V, Piyaraj P, Yoocharoen P, Nittayasoot N, Tan KR, Davis WW, Chottanapund S.   +8 more
europepmc   +1 more source

Effective treatment of advanced Oropouche virus, Rift Valley fever virus, and Dabie bandavirus infections with 4'-fluorouridine. [PDF]

mBio
Westover JB, Jung KH, Rojas I, Bailey KW, Landinez-Aponte J, Blumeling GR, Mao S, Kolykhalov AA, Natchus MG, Painter GR, Gowen BB.   +10 more
europepmc   +1 more source

Research progress on antiviral drugs and vaccines for severe fever with thrombocytopenia syndrome. [PDF]

Front Immunol
Chen C, Li J, Li J, Huang R, Chen C, Xu J, Zhang Y, Lou Y.   +7 more
europepmc   +1 more source

Optimal dose and safety of intravenous favipiravir in hospitalised patients with SARS-CoV-2 infection: a Phase Ib, open-label, dose-escalating, randomised controlled study

Rowland T, FitzGerald R, Challenger E, Dickinson L, Else LJ, Walker L, Hale C, Shaw V, Kelly C, Lyon R, Gibney J, Dhamani K, Irwin M, Enever Y, Tetlow M, Wood W, Reynolds H, Chiong J, Osanlou O, Pertinez H, Bullock K, Greenhalf W, Owen A, Lalloo DG, Jacobs M, Hiscox JA, Jaki T, Mozgunov P, Saunders G, Griffiths G, Khoo SH, Fletcher TE.   +31 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Favipiravir

Reactions Weekly, 2023
  +12 more sources

Ebola virus dynamics in mice treated with favipiravir

Antiviral Research, 2015
International audienceThe polymerase inhibitor favipiravir is a candidate for the treatment of Ebola virus disease. Here, we designed a mathematical model to characterize the viral dynamics in 20 mice experimentally infected with Ebola virus, which were ...
Vincent Madelain, Lisa Oestereich, Frederik Graw   +2 more
exaly   +3 more sources

Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir

Antiviral Research, 2016
Favipiravir, a viral RNA-dependent RNA polymerase inhibitor, has recently been approved in Japan for influenza pandemic preparedness. Here, we conducted a cell-based screening system to evaluate the susceptibility of influenza viruses to favipiravir.
Emi Takashita, Seiichiro Fujisaki, Gabriele Neumann   +2 more
exaly   +2 more sources

Favipiravir in the Battle with Respiratory Viruses

Mini-Reviews in Medicinal Chemistry, 2022
Abstract: Among antiviral drugs, the vast majority targets only one or two related viruses. The conventional model, one virus - one drug, significantly limits therapeutic options. Therefore, in the strategy of controlling viral infections, there is a necessity to develop compounds with pleiotropic effects.
Anna Majewska, Julia M. Smyk
openaire   +2 more sources

The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model

EBioMedicine, 2021
Rana Abdelnabi, Caroline S Foo, Suzanne J F Kaptein   +2 more
exaly